4. Cingulate Inc. (NASDAQ:CING)
Price: $6.27 per share
Cingulate Inc. (NASDAQ: CING) is positioning itself as a differentiated small-cap biotech stock in the rapidly growing ADHD treatment market, bolstered by the recent closing of a $12 million private placement priced at-the-market under Nasdaq rules. Led by life science–focused investors including affiliates of Falcon Creek Capital, the PIPE financing was completed at $5.04 per share with 80% warrant coverage and a 180-day lock-up period, reinforcing long-term alignment and institutional confidence ahead of key milestones. The transaction not only strengthens Cingulate’s balance sheet but also provides potential total proceeds of up to $21.4 million, supporting operations as the company advances toward the anticipated commercial launch of CTx-1301, subject to FDA approval.
Cingulate is focused on next-generation treatments for attention-deficit/hyperactivity disorder, a chronic neurodevelopmental condition affecting approximately 20 million individuals in the United States, including both pediatric and adult patients. Despite the widespread use of stimulant medications, many existing extended-release ADHD drugs fail to deliver consistent, full-day symptom control, often requiring multiple doses and leaving gaps in therapeutic coverage. Cingulate’s proprietary drug delivery platform is designed to address this unmet need by optimizing active-day symptom management, positioning CTx-1301 as a potential differentiated therapy in a multibillion-dollar central nervous system market.
Importantly, the PIPE financing structure reflects disciplined capital strategy. The preferred stock carries a 12% annualized interest rate until conversion, and warrants are exercisable upon stockholder approval with a three-year term, providing flexibility while limiting immediate dilution. Insider participation and board representation rights for Falcon Creek Capital, including the return of experienced pharmaceutical executive Jeff Hargroves, signal strategic alignment and governance support during a critical inflection period. As Cingulate moves closer to regulatory and commercialization milestones, strengthened liquidity, institutional backing, and a focused ADHD pipeline enhance its profile as a catalyst-driven biotechnology company. For investors seeking exposure to innovative CNS therapeutics with near-term commercialization potential, CING stock offers a high-risk, high-reward opportunity tied to the evolving ADHD treatment landscape.
Click next to see the following stock...
